Table of Contents Author Guidelines Submit a Manuscript

An erratum for this article has been published. To view the erratum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 120732, 9 pages
Review Article

Nigella sativa and Its Protective Role in Oxidative Stress and Hypertension

1Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
2Department of Clinical Oral Biology (Pharmacology), Faculty of Dentistry, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
3Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 1 November 2012; Accepted 31 January 2013

Academic Editor: Waris Qidwai

Copyright © 2013 Xin-Fang Leong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hypertension increases the risk for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, and peripheral vascular disease. The increase in oxidative stress has been associated with the pathogenesis of hypertension. Increase of blood pressure is due to an imbalance between antioxidants defence mechanisms and free radical productions. Excessive production of reactive oxygen species reduces nitric oxide bioavailability leading to an endothelial dysfunction and a subsequent increase in total peripheral resistance. Hypertension can cause few symptoms until it reaches the advanced stage and poses serious health problems with lifelong consequences. Hypertensive patients are required to take drugs for life to control the hypertension and prevent complications. Some of these drugs are expensive and may have adverse reactions. Hence, it is timely to examine scientifically, complimentary therapies that are more effective and with minimal undesirable effects. Nigella sativa (NS) and its active constituents have been documented to exhibit antioxidant, hypotensive, calcium channel blockade and diuretic properties which may contribute to reduce blood pressure. This suggests a potential role of NS in the management of hypertension, and thus more studies should be conducted to evaluate its effectiveness.

1. Introduction

According to The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, hypertension is diagnosed as systolic blood pressure (BP) which is greater than 140 mmHg and/or diastolic BP which is greater than 90 mmHg [1]. The prevalence of hypertension in most developing countries is comparable to the developed countries [2, 3]. Hypertension is a major global health disorder due to prolonged human life span. Familial influence and environmental factors such as obesity, sedentary life style, and unhealthy dietary habit contribute to the high prevalence of hypertension [46]. The prevalence of hypertension in Malaysians aged 30 years and above was 42.6% in year 2006, a relative increase of 30% compared to 10 years earlier [7]. In the year 2000, it was estimated about 972 million world’s adult population had hypertension. This number will increase to 1.56 billion by the year 2025 [8].

In recent years, there has been a growing interest and demand in using medicinal plants for treating and preventing various diseases including cardiovascular diseases. Traditional medicines of plants origin have received much attention due to several factors such as easy availability, affordable cost, safety, and efficacy as well as cultural acceptability. Nigella sativa (NS), or also known as black cumin or its Arabic name habat-ul sauda, has been used for centuries in medicinal and culinary purposes throughout the Middle East, India, and Northern Africa. It is an annual flowering plant with pale blue flowers that belongs to the Ranunculaceae family. The plant has a fruit which contains angular black seeds, and the seeds are considered to be the most valuable part contributing beneficial health effects. NS as a natural remedy has been documented to possess numerous therapeutic values, including diabetes, tumour, hypercholesterolemia, hypertension, inflammation, and gastrointestinal disorders [914]. The present paper is, therefore, to examine the current literature on the cardiovascular protective effects of NS and its constituents against oxidative stress and hypertension in addition to the possible mechanisms of actions underlying these beneficial effects.

2. Nigella sativa (NS)

The seed oil of NS was found to be rich in polyphenols and tocopherols [25, 26]. The seeds contain 36–38% fixed oils, 0.4–2.5% essential (volatile) oil, proteins, alkaloids, and saponins [27]. The fixed oil is composed mainly of fatty acids, namely, linoleic (C18:2), oleic (C18:1), palmitic (C16:0), and stearic (C18:0) acids [28]. Thymoquinone (TQ) is the most pharmacologically active ingredient found abundantly (30–48%) in the black seeds, together with its derivatives such as dithymoquinone, thymohydroquinone, and thymol [29].

3. Antioxidant Property of NS

The seed oil of NS is well known for its strong antioxidant properties [30]. Previous studies have documented that pre-treatment with TQ, the main active constituents in seed oil, protected organs against oxidative damage induced by a variety of free radical generating agents, such as carbon tetrachloride [31] and including the alkylating agents, cisplatin [32], and doxorubicin [33]. The free radical scavenging effects of TQ, dithymoquinone, and thymol were tested against several reactive oxygen species (ROS) [34]. All the tested compounds from NS exerted strong antioxidant effects; thymol acted as singlet oxygen quencher, while TQ and dithymoquinone showed superoxide dismutase (SOD)-like activity [34]. In addition, a study carried out by Mansour et al. [35] revealed that both TQ and dithymoquinone acted not only as superoxide anion scavengers, but also as general free radical scavengers with half maximal inhibitory concentration (IC50) in the nanomolar and micromolar ranges, respectively. These findings suggest the importance of such free radical scavenging compounds in the treatment of hypertension which is closely associated with oxidative stress.

TQ is a potent superoxide radical scavenger which is as effective as SOD against superoxides generated either photochemically, biochemically, or derived from calcium ionophore (A23817) [36]. Furthermore, TQ has an inhibitory effect on lipid peroxidation induced by Fe3+/ascorbate. In rats, TQ is protective against doxorubicin-induced cardiotoxicity by reducing the elevation of serum lactate dehydrogenase and creatine phosphokinase levels [36]. Ismail et al. [37] showed that both TQ-rich fraction and TQ markedly improved plasma antioxidant status by inhibiting formation of hydroxyl radicals. Moreover, liver antioxidant enzymes (SOD and glutathione peroxidase GPx) are significantly increased in rats treated with TQ-rich fraction and TQ. In the same study, both TQ-rich fraction and TQ caused an enhanced expression of antioxidant genes (SOD-1, catalase CAT, and GPx-2) in hypercholesterolemic rats [37].

Erşahin et al. [38] reported that NS oil with its potent free radical scavenging properties, inhibited subarachnoid-haemorrhage-(SAH-) induced lipid peroxidation of the brain tissue in rat against the reactive hydroxyl, peroxyl, and superoxide radicals. In addition, the level of antioxidant glutathione (GSH) was preserved [38], thereby ameliorating oxidative damage. The SAH-induced reduction of Na+/K+-ATPase activity indicated the presence of membrane damage. The Na+/K+-ATPase is involved in the generation of the membrane potential through the active transport of sodium and potassium ions in cellular membrane. It maintains neuronal excitability and controls cellular volume in the central nervous system. Treatment with NS oil was able to restore Na+/K+-ATPase activity back to normal levels [38].

Administration of TQ restored the activities of nonenzymatic (GSH and vitamin C) and enzymatic (SOD, CAT, GPx, and glutathione-S-transferase GST) antioxidants as well as reduced the levels of malondialdehyde (MDA) in the rat brain to normal levels [39]. Besides that, TQ supplementation resulted in a complete reversal of the gentamicin-(GM-) induced increase in blood urea nitrogen, creatinine, thiobarbituric acid reactive substances (TBARS), and nitric oxide (NO) and decrease in GSH, GPx, CAT, and adenosine triphosphate (ATP) to control values [40]. Histopathological examination of kidney tissues was in agreement with the biochemical data, wherein TQ supplementation prevented GM-induced degenerative changes in kidney tissues [40]. The findings from this study demonstrated the strong protective effect of TQ by its ability to decrease oxidative stress and to preserve the activities of the antioxidant enzymes [40].

4. Pathogenesis of Hypertension

4.1. Role of Oxidative Stress in Hypertension

Free radicals possess one or more unpaired electrons in their outer electronic orbits. ROS such as superoxide anion ( ), hydroxyl radical (OH-), hydrogen peroxide (H2O2), and singlet oxygen (1O2) are highly reactive. Free radicals and ROS are formed continuously in normal physiological process [41]. However, excessive production leads to oxidative stress with an increase in the formation of nitrogen-oxygen derivative free radicals as well as a decrease in antioxidant capacity [42].

Oxidative stress occurs when there is an imbalance between production of ROS and antioxidant defence system in favour of the former [43, 44]. ROS are highly reactive and unstable by nature; hence, they can damage various cellular components including lipid membranes. Lipid peroxides are derived from polyunsaturated fatty acid (PUFA) oxidation and are capable to initiate lipid peroxidation via free radicals chain reaction. MDA is a major end product of PUFA peroxidation and is often used as an indicator of cell injury.

Increase in the production of MDA may be due to the formation of reactive oxidants. Lipid peroxidation leads to structural changes of the lipid molecules, and the changes are more severe as lipids are the main constituent of biological membranes. Generally, lipid peroxides pose a risk factor for atherosclerotic complications. Increase in free radical formation is linked to a reduction in NO generation [45]. Elevation in serum MDA level found in hypertensive patients suggests a relationship with the increased oxidative stress [46].

Endothelium-derived relaxing factor (EDRF) or better known as NO plays an important regulatory role in the maintenance of vascular homeostasis. BP is regulated by cardiac output and peripheral resistance of blood vessels. NO causes vasodilatation, subsequently reducing total peripheral resistance. Endothelial dysfunction is associated with abnormal endothelium-dependent relaxation as observed in hypertension [4749]. Reduced NO bioavailability, that is, a reduction in NO production by free radicals or an increase in deactivation of NO due to imbalance between antioxidant and oxidant levels may be the mechanism underlying endothelium dysfunction.

NO is synthesized predominantly in the vascular endothelium. Endothelial nitric oxide synthase (eNOS) is required for the synthesis of NO from amino acid L-arginine. There are two other isoforms of NOS, namely, neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS). Both eNOS and nNOS are constitutive enzymes that are produced in normal physiological process, while iNOS is mainly induced during inflammation. NO is small in size and lipophilic by nature. This allows NO to diffuse rapidly through cell membranes to the adjacent smooth muscle cells. Eventually, NO activates guanylate cyclase (GC), and stimulates the formation of cyclic guanosine monophosphate (cGMP) that leads to vascular smooth muscle relaxation. Generation of ROS such as superoxide anions may cause cellular injury by oxidizing membrane lipids, proteins, and nucleic acids. Furthermore, superoxide anions may reduce NO bioavailability by binding to the gaseous molecule and forming peroxynitrite which itself is a free radical [50].

Angiotensin-converting enzyme (ACE) plays a vital role in the regulation of BP and electrolytes balance. ACE is mainly located on the surface of endothelium and epithelium. It hydrolyses angiotensin I (Ang I) to angiotensin II (Ang II), a potent vasoconstrictor and aldosterone-stimulating peptide. Ang II is an important factor in cardiovascular homeostasis [51]. The importance of ACE in maintaining the BP can be observed via the beneficial effect of ACE inhibitors in treating hypertension [52, 53]. Ang II induces oxidative stress via activation of nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase and the production of ROS [54]. In addition to that, Ang II increases lipid peroxidation [55] and stimulates the production of prooxidant cytokines [56, 57], in which these subsequently lead to elevation of BP. Ang II decreases NOS expression and stimulates the generation of ROS [54].

Ang II-induced hypertension is associated with increased vascular superoxide production and impaired vasorelaxation to acetylcholine [54]. Ang II exacerbates oxidative stress, and the increase in the superoxide level could result in endothelial dysfunction via scavenging NO and decreasing NO bioavailability [58]. Hence, the NO-Ang II imbalance may be an important component in the vascular pathophysiology of hypertension. Ang II has been suggested to cause an increase in oxidized low-density lipoprotein cholesterol (ox-LDL) uptake, eventually causing endothelial cell injury [59]. On the other hand, it has also been suggested that ox-LDL upregulates Ang II type 1 receptor expression [60]. These observations may indicate the presence of a relationship between ox-LDL and rennin-angiotensin systems in hypertension. Hence, these two systems may be responsible for the development of endothelial dysfunction, leading to an increase in BP.

4.2. Evidences of Oxidative Stress Involved in Hypertension

There has been a growth evidence suggesting that hypertension may be attributable to the increased production of ROS [61, 62]. Oxidative stress may play a vital role in the development of hypertension via the following mechanisms: enhanced sequestration of NO by ROS [63], formation of lipid peroxidation products [64], and depletion of NOS cofactor (tetrahydrobiopterin) [65]. Lastly, it may cause functional and structural changes in vascular wall and blood vessel [66]. These vascular alterations may be mediated by several ways, including direct injury to endothelial and vascular smooth muscle cells, effects on endothelial cell eicosanoid metabolism, altered redox state, increases in intracellular free calcium concentration, stimulation of inflammatory, and growth signalling events [67, 68].

Oxidative stress promotes proliferation of vascular smooth muscle cells as well as collagen deposition which cause thickening of tunica media and narrowing of the vascular lumen [69], which eventually leads to an increase in the total peripheral resistance. Furthermore, increase in oxidative stress may damage the endothelium and impair endothelium-dependent vasodilatation, consequently increasing vascular contractile activity [69]. ROS may also induce endothelial permeability with the recruitment of inflammatory protein and cells, in which can compromise endothelial function and worsen vascular damage [70]. All these observed effects on the vasculature further support the pathological role of oxidative stress in hypertension.

Amanullah et al. [70] reported that higher MDA levels and lower antioxidant activities such as SOD, GSH, and GPx in hypertensive subjects may be due to increased production of free radicals, indicating the presence of oxidative stress in hypertension. There were notable a positive correlation between BP and lipid peroxidation products in the hypertensives and a negative correlations between BP with plasma antioxidant capacity, plasma vitamin C levels, erythrocyte activity of antioxidant enzymes, and erythrocyte reduced/oxidized glutathione (GSH/GSSG) ratio [71]. These findings demonstrated a possible role of oxidative stress in the pathophysiology of hypertension. In another study, hypertensive patients exhibited higher plasma lipid peroxides along with decreased nonenzymatic antioxidant levels, which could be associated with oxidative stress and depleted antioxidant defence potential [72]. Oxidative stress may occur due to a reduction in antioxidant activities or due to an elevation in ROS concentration. This can lead to oxidative damage to the structure of biomolecules which mostly involve the antioxidant enzymes, thus contributing to the oxidative stress in hypertensives instead of normotensive subjects.

A variety of antioxidant treatments ameliorate hypertension in animal and human studies. Veratric acid, a phenolic acid, was found to decrease the BP, significantly restored NO, enzymatic and nonenzymatic antioxidants, and reduced lipid peroxidation products against L-NG-nitroarginine methyl ester-(L-NAME-) induced hypertension in Wistar rats [73]. Park et al. [74] demonstrated that soy isoflavone supplementation elevated serum NO and total radical trapping antioxidant potential (TRAP) with a reduction in systolic BP after 30 days of feeding period to spontaneously hypertensive rats (SHRs). The results suggest that protective effect of isoflavone against hypertension occurs possibly via the mitigation of oxidative stress and augmentation of NO production. Consumption of green tea which possess strong antioxidant polyphenols was able to reduce BP, serum tumour necrosis factor-α, c-reactive protein, and triglycerides, and total and low-density lipoprotein cholesterol while increasing total antioxidant status and high-density lipoprotein cholesterol in patients with obesity-related hypertension [75].

Administration of vitamins C and E for eight weeks in patients with essential hypertension (EH) had significantly lowered systolic BP, diastolic BP, and mean arterial pressure compared to placebo [76]. The BP reduction was associated with higher erythrocyte and serum antioxidant capacity. BP correlated positively with plasma 8-isoprostane levels and negatively with ferric reducing ability of plasma (FRAP) levels in the vitamins C and E and placebo-treated groups [76]. The findings support the view that oxidative stress is involved in the pathogenesis of EH and that enhancement of antioxidant status by supplementation with vitamins C and E in patients with EH is associated with reduced BP. Hence, this suggests that intervention with antioxidants is a potential adjunct therapy for hypertension.

5. Possible Pharmacological Actions of NS against Hypertension

The exact mechanism on how NS reduces BP is not exactly known. The antihypertensive effects of NS may be due to the many active compounds, each with distinct mechanisms of actions. There are several possible mechanisms involved in BP reduction, which include cardiac depressant effect, calcium channels blocking property, and diuretic effect. Table 1 summarized the effects of NS and its active compounds on BP.

Table 1: Significant cardiovascular effects of NS and its constituents.
5.1. Cardiac Depressant

Previous studies reported that the volatile oil and TQ decreased both the arterial BP and heart rate [15, 16]. The effects of NS on BP and heart rate were reversed by cyproheptadine (a nonselective serotonin receptor blocker) and atropine (antimuscarinic M2 agent) [15, 16]. This finding suggests that the protective effects of NS were mainly mediated centrally either directly or indirectly via mechanisms involving serotoninergic and muscarinic receptors [15, 16]. In contrary, El-Tahir et al. [17] documented that de-thymoquinonated volatile oil, α-pinene, and p-cymene from NS reduced BP and heart rate. However, hypotensive effect of NS was not reversed by atropine or cyproheptadine although these two drugs antagonized the effect of NS on heart rate [17].

The cardiac depressant effects of NS in the rats were significantly reversed by hexamethonium (a ganglionic blocker) suggesting a mechanism involving nicotinic receptors [17]. In addition, destruction of connection between the vasomotor centre in the medulla and preganglionic sympathetic by spinal pithing prevented NS-induced cardiovascular changes [17]. Therefore, the cardiac depressant and hypotensive effects of NS appeared to be mediated via central mechanism involving vasomotor centre in the medulla and sympathetic outflow to the periphery.

Failure of indomethacin (prostaglandin cyclooxygenase inhibitor), mepacrine and hydrocortisone (phospholipase A2 inhibitor), mepyramine (histamine H1 receptor blocker), ranitidine (histamine H2 receptor blocker), and methylene blue (NO-cGMP formation antagonist) to affect NS-induced cardiovascular depressant effects suggests a lack of involvement of eicosanoid, histaminergic, platelet-activating factor (PAF), and NO-induced mechanisms [17].

5.2. Calcium Channel Blockade

Thymol, another active compound of NS, has been documented to be able to reduce BP via its action on calcium (Ca2+) ion channels. Peixoto-Neves et al. [18] reported that thymol produced dose-dependent relaxation in rat isolated aorta. The NS-induced endothelium-independent relaxation may be mediated via mechanisms involving inhibition of Ca2+ release from sarcoplasmic reticulum, reduced Ca2+ sensitivity of the contractile system, and/or blockade of Ca2+ influx across the membrane [18]. Thymol induced a dose-dependent negative inotropic action on both canine and guinea-pig isolated cardiac preparations [19]. The observed effect may be due to a decrease in Ca2+ content in sarcoplasmic reticulum via inhibition of Ca2+ channel [19]. Effect of thymol on Ca2+ current in human and canine ventricular cardiomyocytes was investigated. Magyar et al. [77] demonstrated that thymol inhibits L-type Ca2+ current in a dose-dependent manner. When Ca2+ channels are blocked, Ca2+ entry into vascular smooth muscles is reduced eventually leading to an increase in vasorelaxation.

5.3. Diuretic

The kidney plays a vital role in the control of BP and in the pathogenesis of hypertension. Zaoui et al. [20] reported that 0.6 mL/kg of NS extract for 15 days caused 16% increase in diuresis in SHRs. The diuretic effect of NS was comparable to 5 mg/kg of furosemide which is a high ceiling diuretic. The diuretic effect was associated with an increase in urinary excretion of Na+, K+, Cl-, and urea [20]. This suggests that NS may decrease BP via its diuretic action. A reduction in electrolytes and water content leading to decrease in blood volume, which subsequently reducing cardiac output, is one of the main determinants for BP regulation. In another study, NS extract also demonstrated similar results with an increase in glomerular filtration rate, urinary, and electrolyte output [21]. Rennin-angiotensin-aldosterone (RAA) systems may contribute in regulating BP by controlling blood volume and peripheral vascular resistance. However, the observed effects of NS extract neither have influence on plasma ACE nor rennin activities of SHRs after 20 days of treatment [21]. Therefore, antihypertensive action of NS seems to be independent of RAA system. Nevertheless, more studies need to be performed to evaluate this hypothesis.

6. Conclusion

The cardiovascular protective effects of NS in hypertension are possibly contributed by its multitude actions including cardiac depressant, diuretic, calcium channel blockade, and antioxidant properties (Figure 1). NS is a promising medicinal plant with many therapeutic properties. Various studies have documented the protective effects of NS on the cardiovascular system against the damaging effects of various ROS, protecting the heart from cardiotoxicity as well as reducing adverse effects due to ROS involved in hypertension. NS has been used as a traditional medicine for the treatment of hypertension for many years with no report of adverse events. Further studies should be carried out on human to confirm its efficacy. It is an important area for further research and development to combine NS with other antihypertensive drugs to investigate their possible synergistic effects and preferable pharmacological properties.

Figure 1: Proposed pathways for Nigella sativa (NS) in reducing blood pressure (BP). Ca2+, calcium (II) ion; Na+, sodium ion; K+, potassium ion; Cl-, chloride ion; HR, heart rate; CO, cardiac output; TPR, total peripheral resistance.


  1. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” The Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Khor, “Cardiovascular epidemiology in the Asia-Pacific region,” Asia Pacific Journal of Clinical Nutrition, vol. 10, no. 2, pp. 76–80, 2001. View at Google Scholar · View at Scopus
  3. H. H. Vorster, “The emergence of cardiovascular disease during urbanisation of Africans,” Public Health Nutrition, vol. 5, no. 1A, pp. 239–243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. P. B. Mellen, S. K. Gao, M. Z. Vitolins, and D. C. Goff Jr., “Deteriorating dietary habits among adults with hypertension: dash dietary accordance, NHANES 1988–1994 and 1999–2004,” Archives of Internal Medicine, vol. 168, no. 3, pp. 308–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Schuur, J. C. van Switen, S. Schol-Gelok et al., “Genetic risk factors for cerebral small-vessel disease in hypertensive patients from a genetically isolated population,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 1, pp. 41–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. P. Shook, D. Lee, X. Sui et al., “Cardiorespiratory fitness reduces the risk of incident hypertension associated with a parental history of hypertension,” Hypertension, vol. 59, no. 6, pp. 1220–1224, 2012. View at Publisher · View at Google Scholar
  7. Institute for Public Health, The Third National Health and Morbidity Survey (NHMS III) 2006, Ministry of Health, Putrajaya, Malaysia, 2008.
  8. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Meddah, R. Ducroc, M. El Abbes-Faouzi et al., “Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats,” Journal of Ethnopharmacology, vol. 121, no. 3, pp. 419–424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. N. Nagi and H. A. Almakki, “Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity,” Phytotherapy Research, vol. 23, no. 9, pp. 1295–1298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Kocyigit, Y. Atamer, and E. Uysal, “The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats,” Saudi Medical Journal, vol. 30, no. 7, pp. 893–896, 2009. View at Google Scholar · View at Scopus
  12. N. Taşar, Ö. Şehirli, Ö. Yiğner et al., “Protective effects of Nigella sativa against hypertension-induced oxidative stress and cardiovascular dysfunction in rats,” Marmara Pharmaceutical Journal, vol. 16, no. 2, pp. 141–149, 2012. View at Google Scholar
  13. A. Ghannadi, V. Hajhashemi, and H. Jafarabadi, “An investigation of the analgesic and anti-inflammatory effects of Nigella sativa seed polyphenols,” Journal of Medicinal Food, vol. 8, no. 4, pp. 488–493, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Terzi, S. Coban, F. Yildiz et al., “Protective effects of Nigella sativa on intestinal ischemia-reperfusion injury in rats,” Journal of Investigative Surgery, vol. 23, no. 1, pp. 21–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. K. E. H. El-Tahir, M. M. Ashour, and M. M. AlHarbi, “The cardiovascular actions of the volatile oil of the black seed (Nigella sativa) in rats: elucidation of the mechanism of action,” General Pharmacology, vol. 24, no. 5, pp. 1123–1131, 1993. View at Google Scholar · View at Scopus
  16. K. E. H. El-Tahir and A. M. Ageel, “Effect of volatile oil of Nigella sativa on the arterial blood pressure and heart rate of the guinea-pig,” Saudi Pharmaceutical Journal, vol. 2, no. 4, pp. 163–168, 1994. View at Google Scholar
  17. K. E. H. El-Tahir, M. F. Al-Ajmi, and A. M. Al-Bekairi, “Some cardiovascular effects of the dethymoquinonated Nigella sativa volatile oil and its major components α-pinene and p-cymene in rats,” Saudi Pharmaceutical Journal, vol. 11, no. 3, pp. 104–110, 2003. View at Google Scholar · View at Scopus
  18. D. Peixoto-Neves, K. S. Silva-Alves, M. D. Gomes et al., “Vasorelaxant effects of the monoterpenic phenol isomers, carvacrol and thymol, on rat isolated aorta,” Fundamental and Clinical Pharmacology, vol. 24, no. 3, pp. 341–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Szentandrássy, G. Szigeti, C. Szegedi et al., “Effect of thymol on calcium handling in mammalian ventricular myocardium,” Life Sciences, vol. 74, no. 7, pp. 909–921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Zaoui, Y. Cherrah, M. A. Lacaille-Dubois, A. Settaf, H. Amarouch, and M. Hassar, “Diuretic and hypotensive effects of Nigella sativa on the spontaneously hypertensive rat,” Therapie, vol. 55, no. 3, pp. 379–382, 2000. View at Google Scholar · View at Scopus
  21. N. A. Zeggwagh, A. Moufid, A. Khaldi, J. B. Michel, and M. Eddouks, “Cardiovascular effect of Nigella sativa aqueous extract in spontaneously hypertensive rats,” in Chemistry and Medicinal Value, V. K. Singh and J. N. Govil, Eds., pp. 243–252, Studium Press, Houston, Tex, USA, 2009. View at Google Scholar
  22. M. M. Khattab and M. N. Nagi, “Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats,” Phytotherapy Research, vol. 21, no. 5, pp. 410–414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Sayed, H. A. A. El-Latif, N. I. Eid, A. Z. Elsayed, and E. M. A. El-Kader, “Potential antihypertensive and antioxidative effects of Nigella sativa seeds or biomass and Syzygium aromaticum extracts on L-NAME-induced hypertensive rats,” Egyptian Journal of Pharmaceutical Sciences, vol. 50, pp. 127–146, 2009. View at Google Scholar
  24. F. R. Dehkordi and A. F. Kamkhah, “Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension,” Fundamental and Clinical Pharmacology, vol. 22, no. 4, pp. 447–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Meziti, H. Meziti, K. Boudiaf, B. Mustapha, and H. Bouriche, “Polyphenolic profile and antioxidant activities of Nigella sativa seed extracts in vitro and in vivo,” World Academy of Science, Engineering and Technology, vol. 64, no. 6, pp. 24–32, 2012. View at Google Scholar
  26. G. Al-Naqeeb, M. Ismail, and A. S. Al-Zubairi, “Fatty acid profile, α-tocopherol content and total antioxidant activity of oil extracted from Nigella sativa seeds,” International Journal of Pharmacology, vol. 5, no. 4, pp. 244–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Ali and G. Blunden, “Pharmacological and toxicological properties of Nigella sativa,” Phytotherapy Research, vol. 17, no. 4, pp. 299–305, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Nergiz and S. Otles, “Chemical composition of Nigella sativa L. seeds,” Food Chemistry, vol. 48, no. 3, pp. 259–261, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. O. A. Ghosheh, A. A. Houdi, and P. A. Crooks, “High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.),” Journal of Pharmaceutical and Biomedical Analysis, vol. 19, no. 5, pp. 757–762, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. O. A. Badary, R. A. Taha, A. M. Gamal El-Din, and M. H. Abdel-Wahab, “Thymoquinone is a potent superoxide anion scavenger,” Drug and Chemical Toxicology, vol. 26, no. 2, pp. 87–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. M. N. Nagi, K. Alam, O. A. Badary, O. A. Al-Shabanah, H. A. Al-Sawaf, and A. M. Al-Bekairi, “Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism,” Biochemistry and Molecular Biology International, vol. 47, no. 1, pp. 153–159, 1999. View at Google Scholar · View at Scopus
  32. O. A. Badary, M. N. Nagi, O. A. Al-Shabanah, H. A. Al-Sawaf, M. O. Al-Sohaibani, and A. M. Al-Bekairi, “Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity,” Canadian Journal of Physiology and Pharmacology, vol. 75, no. 12, pp. 1356–1361, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. O. A. Al-Shabanah, O. A. Badary, M. N. Nagi, N. M. Al-Garably, A. C. Al-Rikabi, and A. M. Al-Bekairi, “Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity,” Journal of Experimental and Clinical Cancer Research, vol. 17, no. 2, pp. 193–198, 1998. View at Google Scholar · View at Scopus
  34. I. Kruk, T. Michalska, K. Lichszteld, A. Kladna, and H. Y. Aboul-Enein, “The effect of thymol and its derivatives on reactions generating reactive oxygen species,” Chemosphere, vol. 41, no. 7, pp. 1059–1064, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Mansour, M. N. Nagi, A. S. El-Khatib, and A. M. Al-Bekairi, “Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and dt-diaphorase in different tissues of mice: a possible mechanism of action,” Cell Biochemistry and Function, vol. 20, no. 2, pp. 143–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. M. N. Nagi and M. A. Mansour, “Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection,” Pharmacological Research, vol. 41, no. 3, pp. 283–289, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Ismail, G. Al-Naqeep, and K. W. Chan, “Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats,” Free Radical Biology and Medicine, vol. 48, no. 5, pp. 664–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Erşahin, H. Z. Toklu, D. Akakin, M. Yuksel, B. C. Yeğen, and G. Sener, “The effects of Nigella sativa against oxidative injury in a rat model of subarachnoid hemorrhage,” Acta Neurochirurgica, vol. 153, no. 2, pp. 333–341, 2011. View at Publisher · View at Google Scholar
  39. B. Y. Sheikh and A. M. Mohamadin, “Thymoquinone a potential therapy for cerebral oxidative stress,” Asian Journal of Natural and Applied Sciences, vol. 1, no. 2, pp. 76–92, 2012. View at Google Scholar
  40. M. M. Sayed-Ahmed and M. N. Nagi, “Thymoquinone supplementation prevents the development of gentamicin-induced acute renal toxicity in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 5-6, pp. 399–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Urso and P. M. Clarkson, “Oxidative stress, exercise, and antioxidant supplementation,” Toxicology, vol. 189, no. 1-2, pp. 41–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Grotto, L. Santa Maria, J. Valentini et al., “Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification,” Quimica Nova, vol. 32, no. 1, pp. 169–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. L. B. Ceretta, G. Z. Réus, H. M. Abelaira et al., “Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats,” Experimental Diabetes Research, vol. 2012, Article ID 302682, 8 pages, 2012. View at Publisher · View at Google Scholar
  44. A. M. Raut, A. N. Suryakar, and D. Mhaisekar, “Study of oxidative stress in relation with antioxidant status in chronic bronchitis,” International Journal of Medicine and Medical Sciences, vol. 4, no. 2, pp. 75–77, 2012. View at Google Scholar
  45. M. C. Armas-Padilla, M. J. Armas-Hernández, B. Sosa-Canache et al., “Nitric oxide and malondialdehyde in human hypertension,” The American Journal of Therapeutics, vol. 14, no. 2, pp. 172–176, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. K. S. Meera, “Oxidative imbalance in smokers with and without hypertension,” Biomedical Research, vol. 22, no. 3, pp. 267–272, 2011. View at Google Scholar · View at Scopus
  47. S. Verma and T. J. Anderson, “Fundamentals of endothelial function for the clinical cardiologist,” Circulation, vol. 105, no. 5, pp. 546–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. M. K. Nishizaka, M. A. Zaman, S. A. Green, K. Y. Renfroe, and D. A. Calhoun, “Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism,” Circulation, vol. 109, no. 23, pp. 2857–2861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. X.-F. Leong, M. R. Mustafa, S. Das, and K. Jaarin, “Association of elevated blood pressure and impaired vasorelaxation in experimental Sprague-Dawley rats fed with heated vegetable oil,” Lipids in Health and Disease, vol. 9, article 66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Peluffo, P. Calcerrada, L. Piacenza, N. Pizzano, and R. Radi, “Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers,” The American Journal of Physiology, vol. 296, no. 6, pp. H1781–H1792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. V. J. Dzau, “Tissue angiotensin and pathobiology of vascular disease a unifying hypothesis,” Hypertension, vol. 37, no. 4, pp. 1047–1052, 2001. View at Google Scholar · View at Scopus
  52. L. M. H. Wing, C. M. Reid, P. Ryan et al., “A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly,” The New England Journal of Medicine, vol. 348, no. 7, pp. 583–592, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. L. C. van Vark, M. Bertrand, K. M. Akkerhuis et al., “Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients,” European Heart Journal, vol. 33, no. 16, pp. 2088–2097, 2012. View at Publisher · View at Google Scholar
  54. S. Rajagopalan, S. Kurz, T. Münzel et al., “Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone,” Journal of Clinical Investigation, vol. 97, no. 8, pp. 1916–1923, 1996. View at Google Scholar · View at Scopus
  55. K. Z. Kȩdziora-Kornatowska, M. Luciak, and J. Paszkowski, “Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors,” IUBMB Life, vol. 49, no. 4, pp. 303–307, 2000. View at Google Scholar · View at Scopus
  56. R. T. Cowling, X. Zhang, V. C. Reese et al., “Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts,” The American Journal of Physiology, vol. 289, no. 3, pp. H1176–H1183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Ruiz-Ortega, M. Ruperez, O. Lorenzo et al., “Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney,” Kidney International, Supplement, vol. 62, no. 82, pp. S12–S22, 2002. View at Google Scholar · View at Scopus
  58. A. A. Elmarakby and J. D. Imig, “Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats,” Clinical Science, vol. 118, no. 4, pp. 291–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. J. L. Mehta and D. Li, “Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 2, no. 1, supplement, pp. S70–S76, 2001. View at Google Scholar · View at Scopus
  60. D. Li, T. Saldeen, F. Romeo, and J. L. Mehta, “Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-κB,” Circulation, vol. 102, no. 16, pp. 1970–1976, 2000. View at Google Scholar · View at Scopus
  61. R. Rodrigo, W. Passalacqua, J. Araya, M. Orellana, and G. Rivera, “Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension,” Journal of Cardiovascular Pharmacology, vol. 42, no. 4, pp. 453–461, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Miyajima, S. Minatoguchi, Y. Ito et al., “Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension,” Hypertension Research, vol. 30, no. 4, pp. 307–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. T. J. Guzik, N. E. J. West, R. Pillai, D. P. Taggart, and K. M. Channon, “Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels,” Hypertension, vol. 39, no. 6, pp. 1088–1094, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. J. L. Cracowski, B. Degano, F. Chabot et al., “Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension,” Chest, vol. 142, no. 4, pp. 869–876, 2012. View at Google Scholar
  65. U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1201–1209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Zalba, G. S. José, M. U. Moreno et al., “Oxidative stress in arterial hypertension role of NAD(P)H oxidase,” Hypertension, vol. 38, no. 6, pp. 1395–1399, 2001. View at Google Scholar · View at Scopus
  67. X. Chen, R. M. Touyz, J. B. Park, and E. L. Schiffrin, “Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR,” Hypertension, vol. 38, no. 3, pp. 606–611, 2001. View at Google Scholar · View at Scopus
  68. E. L. Schiffrin, “Beyond blood pressure: the endothelium and atherosclerosis progression,” The American Journal of Hypertension, vol. 15, no. 10, pp. 115S–122S, 2002. View at Google Scholar · View at Scopus
  69. M. McIntyre, D. F. Bohr, and A. F. Dominiczak, “Endothelial function in hypertension: the role of superoxide anion,” Hypertension, vol. 34, no. 4 I, pp. 539–545, 1999. View at Google Scholar · View at Scopus
  70. M. Amanullah, G. S. Zaman, J. Rahman, and S. S. Rahman, “Lipid peroxidation and the levels of antioxidant enzymes in hypertension,” Free Radicals and Antioxidants, vol. 2, no. 2, pp. 12–18, 2012. View at Publisher · View at Google Scholar
  71. R. Rodrigo, H. Prat, W. Passalacqua, J. Araya, C. Guichard, and J. P. Bächler, “Relationship between oxidative stress and essential hypertension,” Hypertension Research, vol. 30, no. 12, pp. 1159–1167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. H. U. Nwanjo, G. Oze, M. C. Okafor, D. Nwosu, and P. Nwankpa, “Oxidative stress and non-enzymatic antioxidant status in hypertensive patients in Nigeria,” African Journal of Biotechnology, vol. 6, no. 14, pp. 1681–1684, 2007. View at Google Scholar
  73. M. Saravanakumar and B. Raja, “Veratric acid, a phenolic acid attenuates blood pressure and oxidative stress in L-NAME induced hypertensive rats,” European Journal of Pharmacology, vol. 671, no. 1–3, pp. 87–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Park, J. I. Shin, O. J. Park, and M. H. Kang, “Soy isoflavone supplementation alleviates oxidative stress and improves systolic blood pressure in male spontaneously hypertensive rats,” Journal of Nutritional Science and Vitaminology, vol. 51, no. 4, pp. 254–259, 2005. View at Google Scholar · View at Scopus
  75. P. Bogdanski, J. Suliburska, M. Szulinska, M. Stepien, D. Pupek-Musialik, and A. Jablecka, “Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients,” Nutritional Research, vol. 32, no. 6, pp. 421–427, 2012. View at Publisher · View at Google Scholar
  76. R. Rodrigo, H. Prat, W. Passalacqua, J. Araya, and J. P. Bächler, “Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension,” Clinical Science, vol. 114, no. 9-10, pp. 625–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Magyar, N. Szentandrássy, T. Bányász, L. Fülöp, A. Varró, and P. P. Nánási, “Effects of terpenoid phenol derivatives on calcium current in canine and human ventricular cardiomyocytes,” European Journal of Pharmacology, vol. 487, no. 1–3, pp. 29–36, 2004. View at Publisher · View at Google Scholar